Search Results | Blood | American Society of Hematology

1-20 of 110

2 3 4 5

Sort by

Sort Order Select

Journal Articles

Phase I Study of Lenalidomide Combined with Dose-Adjusted EPOCH and Rituximab (EPOCH-R 2 ) in Primary Effusion Lymphoma in Participants with or without HIV (NCT02911142)

Kathryn Lurain, MDMPH, Ramya Ramaswami, MBBS,MPH, Anaida Widell, RN, Irene Ekwede, RN, Ralph Mangusan, DNP, CRNP, Jomy George, PharmD, Elaine S. Jaffe, MD, Stefania Pittaluga, MD PhD, Maryalice Stetler-Stevenson, MD PhD, Mark Roth, MD, Constance M. Yuan, MD PhD, Hao-Wei Wang, MD PhD, Vickie Ann Marshall, Denise Whitby, Thomas S. Uldrick, MD MS, Robert Yarchoan, MD

Blood (2020) 136 (Supplement 1): 8–9.

DOI: https://doi.org/10.1182/blood-2020-137188

Published: 2020

Journal Articles

Deep and Durable Remissions of Relapsed Multiple Myeloma on a First-in-Humans Clinical Trial of T Cells Expressing an Anti-B-Cell Maturation Antigen (BCMA) Chimeric Antigen Receptor (CAR) with a Fully-Human Heavy-Chain-Only Antigen Recognition Domain

Blood (2020) 136 (Supplement 1): 50–51.

DOI: https://doi.org/10.1182/blood-2020-138839

Published: 2020

Journal Articles

Treatment of High Risk (HR) Smoldering Multiple Myeloma (SMM) with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Followed By Lenalidomide Maintenance (-R): A Phase 2 Clinical and Correlative Study

Blood (2020) 136 (Supplement 1): 43–45.

DOI: https://doi.org/10.1182/blood-2020-136148

Published: 2020

Journal Articles

Clinical and biological implications of target occupancy in CLL treated with the BTK inhibitor acalabrutinib

Clinical Trials & Observations

Blood (2020) 136 (1): 93–105.

DOI: https://doi.org/10.1182/blood.2019003715

Published: 2020

Includes: Supplemental data

Journal Articles

Phase I/II Study of Lenalidomide Combined with DA-EPOCH and Rituximab (DA-EPOCH-R 2 ) in Primary Effusion Lymphoma in Patients with or without HIV

Kathryn Lurain, MDMPH, Ramya Ramaswami, MBBS,MPH, Anaida Widell, RN, Irene Ekwede, RN, Jomy George, PharmD, Maryalice Stetler-Stevenson, MD PhD, Mark Raffeld, MD, Constance M. Yuan, MD PhD, Joseph Ziegelbauer, PhD, Frank Maldarelli, MD PhD, William D. Figg, PharmD, Cody Peer, PhD, Seth M. Steinberg, PhD, Denise Whitby, Thomas S. Uldrick, MD MS, Robert Yarchoan, MD

Blood (2019) 134 (Supplement_1): 4096.

DOI: https://doi.org/10.1182/blood-2019-122070

Published: 2019

Journal Articles

Risk-Adapted, Ofatumumab-Based Chemoimmunotherapy and Maintenance in Treatment-Naïve CLL: A Phase II Study

Blood (2019) 134 (Supplement_1): 5474.

DOI: https://doi.org/10.1182/blood-2019-126698

Published: 2019

Journal Articles

T Cells Expressing an Anti-B-Cell Maturation Antigen (BCMA) Chimeric Antigen Receptor with a Fully-Human Heavy-Chain-Only Antigen Recognition Domain Induce Remissions in Patients with Relapsed Multiple Myeloma

Lekha Mikkilineni, MD, Elisabet E. Manasanch, MD, Norris Lam, BS, Danielle Vanasse, BS, Jennifer N. Brudno, MD, Irina Maric, MD MSci, Jeremy J. Rose, MS, Maryalice Stetler-Stevenson, MD PhD, Hao-Wei Wang, MD PhD, Constance M. Yuan, MD PhD, David F. Stroncek, MD, Jennifer Mann, CRNP, Micaela Ganadan, BSN, RN, Rashmika Patel, Nathan Trinklein, PhD, Ben Buelow, MD PhD, Ronald E. Gress, MD, James N. Kochenderfer, MD

Blood (2019) 134 (Supplement_1): 3230.

DOI: https://doi.org/10.1182/blood-2019-129088

Published: 2019

Journal Articles

Long Term Follow-up of a Phase II Study of Cladribine with Concurrent Rituximab in Patients with Hairy Cell Leukemia Variant

Dai Chihara, MD PhD, Evgeny Arons, PhD, Maryalice Stetler-Stevenson, MD PhD, Constance M. Yuan, MD PhD, Hao-Wei Wang, MD PhD, Hong Zhou, Mark Raffeld, MD, Liqiang Xi, MD, Seth M. Steinberg, PhD, Julie Feurtado, RN, Lacey James-Echenique, CRNP, Wyndham Wilson, MD, Raul C. Braylan, MD, Katherine R. Calvo, MD PhD, Irina Maric, MD MSci, Alina Dulau-Florea, MD, Robert J. Kreitman, MD

Blood (2019) 134 (Supplement_1): 1536.

DOI: https://doi.org/10.1182/blood-2019-124515

Published: 2019

Journal Articles

Sequential CD22 Targeting Impacts CD22 CAR-T Cell Response

Bonnie Yates, RN, Haneen Shalabi, DO, Dalia Salem, MD, Cynthia Delbrook, RN, Constance M. Yuan, MD PhD, Maryalice Stetler-Stevenson, MD PhD, Terry J. Fry, MD, Nirali N. Shah, MD

Blood (2018) 132 (Supplement 1): 282.

DOI: https://doi.org/10.1182/blood-2018-99-119621

Published: 2018

Journal Articles

Radiation-Sparing Treatment of HIV-Related Primary Central Nervous System Lymphoma with Antiretroviral Therapy, Rituximab and High-Dose Methotrexate

Kathryn Lurain, MD MPH, Thomas S. Uldrick, MD MS, Priscila H. Goncalves, MD, Ramya Ramaswami, MBBS, MPH, Mark N. Polizzotto, Anaida Widell, Seth M. Steinberg, PhD, Elaine S. Jaffe, Stefania Pittaluga, MD PhD, Maryalice Stetler-Stevenson, MD PhD, Constance M. Yuan, MD PhD, Richard F. Little, MD MPH, Robert Yarchoan, MD

Blood (2018) 132 (Supplement 1): 2963.

DOI: https://doi.org/10.1182/blood-2018-99-112169

Published: 2018

Journal Articles

Low CD19 Antigen Density Diminishes Efficacy of CD19 CAR T Cells and Can be Overcome By Rational Redesign of CAR Signaling Domains

Robbie G. Majzner, MD, Skyler P. Rietberg, Louai Labanieh, Elena Sotillo, PhD, Evan W. Weber, PhD, Rachel C. Lynn, PhD, Johanna L. Theruvath, MD, Constance M. Yuan, MD PhD, Peng Xu, MD, Sang M. Nguyen, BS, Nirali N. Shah, MD, Maryalice Stetler-Stevenson, MD PhD, Terry J. Fry, MD, Daniel W. Lee, MD, Crystal L. Mackall, MD

Blood (2018) 132 (Supplement 1): 963.

DOI: https://doi.org/10.1182/blood-2018-99-115558

Published: 2018

Journal Articles

A Phase 2 Study of Carfilzomib, Lenalidomide, and Dexamethasone with Lenalidomide Maintenance (KRd-r) in Newly Diagnosed Multiple Myeloma (NDMM): Sustained Long Term Deep Remissions and Prolonged Progression-Free Duration Regardless of Age or Cytogenetic Risk after 5 Years of Follow up

Blood (2018) 132 (Supplement 1): 1957.

DOI: https://doi.org/10.1182/blood-2018-99-111712

Published: 2018

Journal Articles

The Role of Novel Dual Color Immunohistochemistry in Detection of Minimal Hairy Cell Leukemia in Bone Marrow: A Study of 148 Cases

Gaurav K. Gupta, MD, Xiaoping Sun, PhD, Constance M. Yuan, MD PhD, Maryalice Stetler-Stevenson, MD PhD, Robert J. Kreitman, MD, Irina Maric, MD MSci

Blood (2018) 132 (Supplement 1): 4859.

DOI: https://doi.org/10.1182/blood-2018-99-116258

Published: 2018

Journal Articles

Molecular Remissions with Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox Are Associated with Improved Complete Remission Durations during Phase I and III Testing

Evgeny Arons, PhD, Daniel Gorelik, Maryalice Stetler-Stevenson, MD PhD, Constance M. Yuan, MD PhD, Mark Sokolsky, Hong Zhou, Nai Shun (nancy) Yao, MD, Shannon Marshall, PhD, Katherine Potocka, Erin Fykes, Ira Pastan, MD, Robert J. Kreitman, MD

Blood (2018) 132 (Supplement 1): 1861.

DOI: https://doi.org/10.1182/blood-2018-99-113419

Published: 2018

Journal Articles

Minimal residual hairy cell leukemia eradication with moxetumomab pasudotox: phase 1 results and long-term follow-up

Clinical Trials & Observations Brief Report

Robert J. Kreitman, Martin S. Tallman, Tadeusz Robak, Steven Coutre, Wyndham H. Wilson, Maryalice Stetler-Stevenson, David J. FitzGerald, Linda Santiago, Guozhi Gao, Mark C. Lanasa, Ira Pastan

Blood (2018) 131 (21): 2331–2334.

DOI: https://doi.org/10.1182/blood-2017-09-803072

Published: 2018

Includes: Supplemental data

Journal Articles

Depth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase 2 study

Blood (2018) 131 (21): 2357–2366.

DOI: https://doi.org/10.1182/blood-2017-12-820910

Published: 2018

Includes: Supplemental data

Journal Articles

High Prevalence of Multiple B Cell Clones in Patients with Chronic Lymphocytic Leukemia

Alankrita Taneja, MBBS, Clare Sun, MD, Constance Yuan, Maryalice Stetler-Stevenson, Susan Soto, Gerald Marti, Adrian Wiestner, MD

Blood (2017) 130 (Supplement 1): 1712.

DOI: https://doi.org/10.1182/blood.V130.Suppl_1.1712.1712

Published: 2017

Journal Articles

Improving Depth of Response with Continued Ibrutinib Therapy in CLL Patients

Inhye E. Ahn, MD, Xin Tian, PhD, Jennifer Lotter, Susan Soto, Janet Valdez, Pia Nierman, Maryalice stetler-Stevenson, Constance Yuan, Irina Maric, Adrian Wiestner, MD

Blood (2017) 130 (Supplement 1): 4302.

DOI: https://doi.org/10.1182/blood.V130.Suppl_1.4302.4302

Published: 2017

Journal Articles

Intensification of Lymphodepletion Optimizes CAR Re-Treatment Efficacy

Haneen Shalabi, DO, Nirali N Shah, MD, Terry J. Fry, MD, Bonnie Yates, RN, Cynthia Delbrook, RN, Constance Yuan, Maryalice Stetler-Stevenson, Sneha Ramakrishna, MD

Blood (2017) 130 (Supplement 1): 3889.

DOI: https://doi.org/10.1182/blood.V130.Suppl_1.3889.3889

Published: 2017

Journal Articles

Combination of Ibrutinib and Short-Course Fludarabine in Previously Untreated Patients with CLL: A Pilot Phase II Study

Inhye E. Ahn, MD, Susan Soto, Pia Nierman, Xin Tian, PhD, Janet Valdez, Jennifer Lotter, Thomas Fleisher, Sergio Rosenzweig, Shakuntala Rampertaap, Irina Maric, Maryalice Stetler-Stevenson, Constance Yuan, Gerald Marti, Adrian Wiestner, MD

Blood (2017) 130 (Supplement 1): 3020.

DOI: https://doi.org/10.1182/blood.V130.Suppl_1.3020.3020

Published: 2017

2 3 4 5

NARROW

Phase I Study of Lenalidomide Combined with Dose-Adjusted EPOCH and Rituximab (EPOCH-R 2 ) in Primary Effusion Lymphoma in Participants with or without HIV (NCT02911142)

Deep and Durable Remissions of Relapsed Multiple Myeloma on a First-in-Humans Clinical Trial of T Cells Expressing an Anti-B-Cell Maturation Antigen (BCMA) Chimeric Antigen Receptor (CAR) with a Fully-Human Heavy-Chain-Only Antigen Recognition Domain

Treatment of High Risk (HR) Smoldering Multiple Myeloma (SMM) with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Followed By Lenalidomide Maintenance (-R): A Phase 2 Clinical and Correlative Study

Clinical and biological implications of target occupancy in CLL treated with the BTK inhibitor acalabrutinib

Phase I/II Study of Lenalidomide Combined with DA-EPOCH and Rituximab (DA-EPOCH-R 2 ) in Primary Effusion Lymphoma in Patients with or without HIV

Risk-Adapted, Ofatumumab-Based Chemoimmunotherapy and Maintenance in Treatment-Naïve CLL: A Phase II Study

T Cells Expressing an Anti-B-Cell Maturation Antigen (BCMA) Chimeric Antigen Receptor with a Fully-Human Heavy-Chain-Only Antigen Recognition Domain Induce Remissions in Patients with Relapsed Multiple Myeloma

Long Term Follow-up of a Phase II Study of Cladribine with Concurrent Rituximab in Patients with Hairy Cell Leukemia Variant

Sequential CD22 Targeting Impacts CD22 CAR-T Cell Response

Radiation-Sparing Treatment of HIV-Related Primary Central Nervous System Lymphoma with Antiretroviral Therapy, Rituximab and High-Dose Methotrexate

Low CD19 Antigen Density Diminishes Efficacy of CD19 CAR T Cells and Can be Overcome By Rational Redesign of CAR Signaling Domains

A Phase 2 Study of Carfilzomib, Lenalidomide, and Dexamethasone with Lenalidomide Maintenance (KRd-r) in Newly Diagnosed Multiple Myeloma (NDMM): Sustained Long Term Deep Remissions and Prolonged Progression-Free Duration Regardless of Age or Cytogenetic Risk after 5 Years of Follow up

The Role of Novel Dual Color Immunohistochemistry in Detection of Minimal Hairy Cell Leukemia in Bone Marrow: A Study of 148 Cases

Molecular Remissions with Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox Are Associated with Improved Complete Remission Durations during Phase I and III Testing

Minimal residual hairy cell leukemia eradication with moxetumomab pasudotox: phase 1 results and long-term follow-up

Depth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase 2 study

High Prevalence of Multiple B Cell Clones in Patients with Chronic Lymphocytic Leukemia

Improving Depth of Response with Continued Ibrutinib Therapy in CLL Patients

Intensification of Lymphodepletion Optimizes CAR Re-Treatment Efficacy

Combination of Ibrutinib and Short-Course Fludarabine in Previously Untreated Patients with CLL: A Pilot Phase II Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only